Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congres...
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Business Wire
- Oral poster showcasing positive results from Revance’s Phase 2 JUNIPER clinical trial, which demonstrated long-term efficacy and safety with DAXXIFY™ for the treatment of upper limb spasticity (ULS) in adults after stroke or traumatic brain injury- Study results indicate that DAXXIFY™ at the 500U dose is effective and well tolerated for treating adult ULS- Study results demonstrated DAXXIFY™ had a median duration of response of 24 weeks NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an oral presentation by Dr. Atul Patel, JUNIPER clinical investigator, will take place on Friday, September 16 at 2:30 pm GMT+ 2 at the International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Madrid, Spain. The presentation will include results from Revance’s JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]Yahoo! Finance
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingBusiness Wire
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
RVNC
Earnings
- 2/28/24 - Beat
RVNC
Sec Filings
- 4/17/24 - Form 4
- 4/9/24 - Form SC
- 3/21/24 - Form DEFA14A
- RVNC's page on the SEC website